Stroke prevention in atrial fibrillation with left atrial appendage closure

Chad Zack, Erin A. Fender, David R. Holmes

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Patients with atrial fibrillation (AF) are at risk for stroke and thromboembolism. Oral anticoagulants (OAC) are effective therapies to reduce the risk of stroke; however, these agents also increase the risk of bleeding complications. Concerns over bleeding contribute to significant under treatment and leave a substantial proportion of patients at risk for a serious or life-threatening stroke. Identification of the left atrial appendage (LAA) as the major site of pathogenic thrombus formation in AF patients has led to the development of devices which exclude the appendage from the systemic circulation. These devices offer a potential alternative treatment for some AF patients who cannot tolerate long term OAC. This article will review the pathogenesis of LAA thrombus formation and identify the patient population most likely to benefit from LAA closure devices. Finally, we will review LAA closure techniques (both surgical and percutaneous), evaluate published outcomes data, and discuss the indications and risk/benefit considerations of each approach.

Original languageEnglish (US)
Pages (from-to)199-211
Number of pages13
JournalMinerva Medica
Issue number3
StatePublished - Jun 2017

All Science Journal Classification (ASJC) codes

  • General Medicine


Dive into the research topics of 'Stroke prevention in atrial fibrillation with left atrial appendage closure'. Together they form a unique fingerprint.

Cite this